Leukocyte Depleted, Unscreened Blood Products Give a Low Risk for CMV Infection and Disease in CMV Seronegative Allogeneic Stem Cell Transplant Recipients with Seronegative Stem Cell Donors
Authors:
- Per LjungmanPLPer Ljungman
- Kajsa LarssonKLKajsa Larsson
- Gunilla KumlienGKGunilla Kumlien
- Johan AschanJAJohan Aschan
- Lisbeth BarkholtLBLisbeth Barkholt
- Åsa Gustafsson-JernbergÅGÅsa Gustafsson-Jernberg
- Ilona Lewensohn-FuchsILIlona Lewensohn-Fuchs
- Olle RingdénOROlle Ringdén
- 1 January 2002
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Infectious Diseases
- Vol. 34 (5) , 347-350
Abstract
Leukocyte depletion (LD) by blood product filtration has been shown to be similarly effective to the use of screened, CMV seronegative blood products to prevent CMV disease in CMV seronegative allogeneic stem cell transplant (SCT) patients with CMV seronegative donors. The aim of this retrospective study was to determine the risk for development of CMV infection requiring preemptive therapy and for CMV disease if unscreened products treated by prestorage LD is used. Forty-nine consecutive patients transplanted after June 1995 were included. As a control group, 33 patients transplanted from January 1992 to June 1995 in whom a combination of CMV seronegative and LD blood products were given. All patients were monitored weekly by a leukocyte-based PCR for CMV DNA detection. Preemptive therapy was initiated after two consecutively positive tests. No patient developed CMV disease in either group. CMV DNA was detected in 6/49 (p = NS) in the study group and in 3/33 patients in the historical control group. Two patients in the study group were given preemptive therapy compared to one patient in the control group. This study suggests that the risk for CMV disease and the need for preemptive therapy against CMV is low in CMV seronegative allogeneic SCT patients receiving grafts from CMV seronegative stem cell donors receiving LD blood products. Thus, this strategy can be safely used together with PCR monitoring and preemptive therapy.Keywords
This publication has 11 references indexed in Scilit:
- Storage of Platelets in Additive Solutions: Effects of PhosphateVox Sanguinis, 2000
- Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over timeTransfusion, 1998
- A system for the supply of platelets suspended in a storage medium including buffy-coat-derived platelet concentrates in combination with “split” apheresis plateletsTransfusion Science, 1997
- Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donorsBone Marrow Transplantation, 1997
- A three-center European external quality control study of PCR for detection of cytomegalovirus DNA in bloodJournal of Clinical Microbiology, 1996
- CYTOMEGALOVIRUS DNA IN PERIPHERAL BLOOD LEUKOCYTES AND PLASMA FROM BONE MARROW TRANSPLANT RECIPIENTSTransplantation, 1995
- Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantationBlood, 1995
- Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study [see comments]Blood, 1995
- CMV PCR monitoring in leucocytes of transplant patientsClinical and Diagnostic Virology, 1995
- Cytomegalovirus Immune Globulin and Seronegative Blood Products to Prevent Primary Cytomegalovirus Infection after Marrow TransplantationNew England Journal of Medicine, 1986